Campbell & Co Investment Adviser’s Myriad Genetics MYGN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,469	Closed	-$55.6K	–	1296
2025 Q2	$55.6K	Sell	10,469 -10,721	-51%	-$63.3K	﹤0.01%	1099
2025 Q1	$188K	Sell	21,190 -105,795	-83%	-$1.27M	0.01%	951
2024 Q4	$1.74M	Buy	+126,985	New	+$2.34M	0.13%	219
2024 Q3	–	Sell	-21,617	Closed	-$529K	–	1244
2024 Q2	$529K	Buy	+21,617	New	+$474K	0.05%	632
2019 Q3	–	Sell	-16,119	Closed	-$448K	–	702
2019 Q2	$448K	Buy	+16,119	New	+$455K	0.2%	173
2016 Q3	–	Sell	-9,902	Closed	-$303K	–	173
2016 Q2	$303K	Buy	+9,902	New	+$344K	1.53%	18

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Campbell & Co Investment Adviser's MYGN Position: Q3 2025 in Review

Campbell & Co Investment Adviser sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 10,469 shares — an estimated $55.6K sold.

Campbell & Co Investment Adviser first reported a position in MYGN in Q2 2016 and held it in 6 quarters. The position peaked at $1.74M in Q4 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

Campbell & Co Investment Adviser reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 10,469 Myriad Genetics shares in Q3 2025, an estimated $55.6K.
Campbell & Co Investment Adviser first reported a position in Myriad Genetics in Q2 2016 and held it in 6 quarters.
Campbell & Co Investment Adviser's Myriad Genetics position peaked at $1.74M in Q4 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2025, filed 28 Oct 2025.